Safety and Immunogenicity of an Intranasal Sendai Virus-Based Human Parainfluenza Virus Type 1 Vaccine in 3- to 6-Year-Old Children

Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model

(2014) Bart G. Jones et al.   VACCINE

Sendai virus-based RSV vaccine protects African green monkeys from RSV infection

(2011) Bart G. Jones et al.   VACCINE

Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the gut

(2011) Rajeev Rudraraju et al.   VIROLOGY

Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1

(2010) R. Sealy et al.   VACCINE

Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV

(2009) Bart Jones et al.   VACCINE

Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections

(2008) Xiaoyan Zhan et al.   VACCINE